Abstract
Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.
| Original language | English |
|---|---|
| Pages (from-to) | 379-386 |
| Number of pages | 8 |
| Journal | Breast |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2003 |
Fingerprint
Keywords
- Breast neoplasms
- Chemoprevention
- Clinical trial
- Tamoxifen
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Pharmacological prevention of breast cancer : Quo Vadis? / Serrano, Davide; Bonanni, Bernardo; Cazzaniga, Massimiliano; Galli, Arianna; Gonzaga, Aliana Guerrieri; Decensi, Andrea.
In: Breast, Vol. 12, No. 6, 12.2003, p. 379-386.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacological prevention of breast cancer
T2 - Quo Vadis?
AU - Serrano, Davide
AU - Bonanni, Bernardo
AU - Cazzaniga, Massimiliano
AU - Galli, Arianna
AU - Gonzaga, Aliana Guerrieri
AU - Decensi, Andrea
PY - 2003/12
Y1 - 2003/12
N2 - Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.
AB - Although tamoxifen reduces breast cancer incidence by 30-40% in at-risk subjects, its adverse events may be a limiting factor. Thus, different strategies are being pursued to improve the risk:benefit ratio of breast cancer chemoprevention intervention. Firstly, raloxifene is being compared with tamoxifen in a phase-III trial, whereas the minimal active dose of tamoxifen is being assessed in phase I-II trials. The combination of HRT and tamoxifen may also reduce the risks while retaining the benefits of either agent. Anastrozole holds promise as a preventive agent based on preliminary data on contralateral breast cancer. Another important area is the appropriate identification of women at increased risk for ER-positive breast cancer due to reproductive factors, which may maximize the therapeutic index of hormonal agents. Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions.
KW - Breast neoplasms
KW - Chemoprevention
KW - Clinical trial
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=0346888600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346888600&partnerID=8YFLogxK
U2 - 10.1016/S0960-9776(03)00140-1
DO - 10.1016/S0960-9776(03)00140-1
M3 - Article
C2 - 14659109
AN - SCOPUS:0346888600
VL - 12
SP - 379
EP - 386
JO - Breast
JF - Breast
SN - 0960-9776
IS - 6
ER -